Dual Vaccination

PCV‐13⁽²⁾⁽³⁾ x single dose, followed by PPSV‐23⁽²⁾ 8 weeks later

• Asplenic

• Sickle cell disease

• Congenital immunodeficiencies

• HIV

• Corticosteroids

• Chemotherapy

• Radiation

• SOT

• Biologics

• Malignancy

• Nephrotic syndrome

• HSCT*

*Patients post‐hematopoietic stem cell transplant (HSCT) should receive 3 doses of PCV‐13⁽²⁾⁽³⁾, spaced apart by 4 weeks each, starting 3‐9 months after transplant followed by PPSV‐23⁽²⁾ 12‐18 months post‐transplant.

PPSV‐23⁽²⁾ booster x 1 recommended ≥5 years after initial pneumococcal vaccination

(1) Live attenuated vaccine
(2) Inactive or component vaccine
(3)

Only covered by MSP for certain indications

PPSV‐23: 23 valent pneumococcal polysaccharide vaccine
PCV‐13: 13 valent pneumococcal conjugate vaccine